NEW YORK – Margaret McGlynn will step down after four years as President and CEO of the International AIDS Vaccine Initiative (IAVI). A search for her successor is underway, led by IAVI’s Board of Directors.
“Margie’s outstanding experience as head of Merck global vaccines and her unique blend of professionalism and dedication have strongly positioned IAVI to provide continued innovation and value to the field of AIDS vaccine research and development,” said IAVI Board Chair Alex Coutinho. “The Board is working diligently to identify the best person to lead IAVI’s next chapter.”
McGlynn joined IAVI’s Board in July 2010 and became President and CEO a year later. She will continue in her role until a new CEO is on board, and will provide additional support as needed during the transition.
“It has been a tremendous privilege to lead IAVI and to work alongside many of the world’s most committed AIDS vaccine researchers, advocates and donors,” said McGlynn, who plans to devote her time and energies to other interests including a rare-disease foundation she created in 2009. “The efforts of IAVI’s talented and dedicated Board, management and staff are augmented by those of an equally impressive group of partners and supporters. Together, we will achieve a world without AIDS.”